FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to medical products used as an ophthalmic agent, containing riboflavin and pharmaceutical aids applied for a cross-linking procedure in corneal ectasias. The agent contains riboflavin mononucleotide, dextran, sodium chloride, tris-(hydroxymethyl)-methylamine, nipagin, trilon and purified distilled water in a certain relation of components.
EFFECT: invention provides prolonged action of the ophthalmic agent, improves its chemical and bacteriological stability in a solution.
1 ex
| Title | Year | Author | Number | 
|---|---|---|---|
| OPHTHALMIC CROSS-LINKING AGENT-2 | 2012 | 
 | RU2475248C1 | 
| OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 | 
 | RU2560669C1 | 
| OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 | 
 | RU2646452C1 | 
| HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 | 
 | RU2631604C1 | 
| METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 | 
 | RU2682494C1 | 
| COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 | 
 | RU2676434C1 | 
| METHOD OF TREATING EPITHELIAL-ENDOTHELIAL CORNEAL DYSTROPHY | 2019 | 
 | RU2703361C1 | 
| METHOD OF CORNEAL GRAFT PREPARATION FOR LAYER-BY-LAYER KERATOPLASTY | 2019 | 
 | RU2723135C1 | 
| HYPO-OSMOTIC OPHTHALMIC AGENT FOR ULTRAVIOLET CROSS-LINKING OF THIN CORNEAS | 2024 | 
 | RU2841327C1 | 
| METHOD OF TREATING HERPETIC KERATITIS | 2013 | 
 | RU2531426C1 | 
Authors
Dates
2011-02-27—Published
2009-10-21—Filed